Giles Robinson
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
Giles Robinson
Feb 19, 2024, 18:12 |
Career
Giles Robinson: Congratulations Sara Federico on being named the director of the Solid Tumor Division at the St. Jude Children’s Research Hospital
Giles Robinson, Neuro-Oncology Division Director at the St. Jude Children’s Research Hospital, shared on X/Twitter:…
Dec 22, 2023, 14:14 |
Blog
Giles Robinson: We’re enrolling infants and young children with medulloblastoma on SJiMB21
Giles Robinson, Neuro-Oncology Division Director at the St. Jude Children’s Research Hospital, shared on X/Twitter:…
Nov 17, 2023, 17:20 |
Blog
Giles Robinson: Loc3Car is the St. Jude Children’s Research Hospital's Brain Tumor Program’s first venture into Car T-Cell therapy
Giles Robinson, Neuro-Oncology Division Director at St. Jude Children’s Research Hospital, shared on X/Twitter: "Loc3Car…
Nov 9, 2023, 21:13 |
Career
Giles Robinson: I’m honored & humbled to follow in the footsteps of Dr Amar Gajjar
Giles Robinson, prominent pediatric neuro-oncologist from St. Jude, shared on X (Twitter): "I’m honored &…
Sep 8, 2023, 12:49 |
Drugs
Amar Gajjar: SJ901 offers a new targeted therapeutic approach against pediatric low-grade gliomas.
Quoting Amar Gajjar on Twitter: ''SJ901, named after the last 3 digits of the experimental…
Aug 1, 2023, 19:34 |
Blog
Congratulations Dr. Jason Chiang, Giles Robinson, Dr. Aditi Bagchi & the members of the Brain Tumor program - Amar Gajjar
Congratulations Dr. Jason Chiang, Giles Robinson, Dr.Aditi Bagch & the members of the Brain Tumor…
All:
6
Posts:
1 - 10
Eliot Levitt: The Yvonne Awards demonstrate something that it doesn't hurt to be reminded of
New data from the NEST clinical trial was presented at ESMOGI24 - Agenus
Zainab Shinkafi-Bagudu's latest commentary on Cervical Cancer Elimination Forum
New Paper Alert! Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results
Learn more about overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube